Sirolimus for the Treatment of Hyperinsulinism

Status Withdrawn

Clinical Trial Summary

The purpose of this pilot study is to generate data to assess feasibility of study design/procedures and for formal sample size estimation for a larger multicenter study of the efficacy and safety of sirolimus in infants with medically-unresponsive congenital hyperinsulinism (HI) due to inactivating mutations of adenosine triphosphate-sensitive potassium (KATP) channels.

Clinical Trial Description

Treatment options for children with diffuse adenosine triphosphate-sensitive potassium (KATP) channel hyperinsulinism (KATPHI) are limited and most of them require a near-total pancreatectomy to control the hypoglycemia. However, at least 40% of these children continue to have persistent hypoglycemia after surgery and their long-term outcomes are complicated by the development of diabetes.

There is evidence that suggests that mammalian target of rapamycin (mTOR) inhibitors are useful in controlling the hypoglycemia in hyperinsulinemic hypoglycemia. But before adapting this as standard therapy for children with hyperinsulinism, a carefully controlled study of the efficacy and safety of sirolimus for hyperinsulinism is clearly needed.

Sirolimus is an mTOR inhibitor, which is FDA-approved for the prophylaxis of organ rejection in patients age 13 years and older receiving kidney transplantation. This is an open label pilot study to assess the effect, safety and tolerability of sirolimus in infants with diazoxide-unresponsive HI due to mutations in the genes encoding the KATP channels. Subjects will be treated with sirolimus for 6 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02524639
Study type	Interventional
Source	Children's Hospital of Philadelphia
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	August 12, 2015
Completion date	May 29, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00074451` - Genomewide Search for Loci Underlying Metabolic Syndrome
Completed	`NCT00073775` - Epidemiology of Stress and the Metabolic Syndrome	N/A
Completed	`NCT00005380` - Insulin, Androgen, and Risk in African-American Women	N/A
Completed	`NCT00005709` - Lipoprotein Metabolism in Hypertensive African-Americans	N/A
Recruiting	`NCT05088798` - Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism	Phase 2
Not yet recruiting	`NCT05950282` - Fasting Insulin and HOMA-IR by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis
Completed	`NCT02248272` - Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes	N/A
Completed	`NCT00937079` - Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients	Phase 1
Completed	`NCT00151684` - Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men	Phase 2
Completed	`NCT00004825` - Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism	N/A
Completed	`NCT00005530` - Diet, Insulin Resistance, and Cardiovascular Risk	N/A
Recruiting	`NCT05662189` - Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus	N/A
Recruiting	`NCT04744896` - Effects Of Combined Cryolipolysis And High Intensity Interval Training On Insulin Resistance And Body Composition In Polycystic Ovarian Patients	N/A
Completed	`NCT05329337` - Link Between the Peripheral Mononuclear Cells' Capacity to Induce Insulin Resistance and Hyperinsulinemia	N/A
Not yet recruiting	`NCT05989347` - Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy	Phase 1
Recruiting	`NCT05543083` - Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes	N/A
Recruiting	`NCT05774613` - Effect of Hibiscus Sabdariffa Beverage	N/A
Recruiting	`NCT06363929` - Continuous Glucose Monitoring in Neonatal Hyperinsulinism
Completed	`NCT03358745` - Impact of Meal Order on Postprandial Cardiometabolic Risk Markers	N/A
Not yet recruiting	`NCT05764200` - Acute Microbial Switch	N/A